Zobrazeno 1 - 10
of 2 068
pro vyhledávání: ''
Publikováno v:
Blood
INTRODUCTION Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent studies have suggested that COVID-19 positive patients present with leu
Autor:
William G. Wierda, Mary Beth Rios, Guilin Tang, Tapan M. Kadia, Gautam Borthakur, Raja Luthra, Graciela M. Nogueras González, Ghayas C. Issa, Keyur P. Patel, Farhad Ravandi, Elias Jabbour, Nicholas J. Short, Guillermo Garcia-Manero, Hagop M. Kantarjian, Koji Sasaki, Jorge E. Cortes, Alessandra Ferrajoli, Sara Dellasala
Publikováno v:
Blood. 130:2084-2091
Clonal chromosomal abnormalities in Philadelphia chromosome-negative (CCA/Ph-) metaphases emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase inhibitors (TKIs). We assessed the characteristics and
Autor:
Deepa Jagadeesh, Anthony R. Mato, Krista Isaac, Allison M. Winter, Brian T. Hill, Nishitha Reddy, Daniel J. Landsburg, Stephen D. Smith, Mitchell R. Smith, Francisco J. Hernandez-Ilizaliturri, Mazyar Shadman, Paolo Caimi
Publikováno v:
Blood. 130:1676-1679
To the editor: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with distinct immunophenotypes, genetic features, and clinical outcomes. Based on differential gene expression, termed cell of origin (COO), DLBCL can be subcategorized i
Autor:
Kishore Kumar, Prabodh Das, Somanath Padhi, Shruti Mishra, Gaurav Chhabra, Ashutosh Panigrahi
Publikováno v:
Blood. 136:19-20
Introduction: Acute promyelocytic leukemia (APL) is one of the hematological emergencies requiring early detection and treatment. The hematology laboratory plays a pivotal role in management. The correct morphological identification of APL is made ev
Autor:
Jonathan W. Friedberg
Publikováno v:
Blood. 130:590-596
The 2016 revision of the World Health Organization (WHO) classification for lymphoma has included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with translocations involving myc and bcl-2 o
Autor:
Stephen Hamilton-Dutoit, Francesco d'Amore, N. Nora Bennani, Torben Steiniche, Rebecca L. Boddicker, Martin Bjerregård Pedersen, Christopher A. Sattler, Michael Boe Møller, Peter Nørgaard, Andrew L. Feldman, Rhett P. Ketterling, Patrick P. Bedroske, Ivy Luoma, Knud Bendix
Publikováno v:
Pedersen, M B, Hamilton-Dutoit, S J, Bendix, K, Ketterling, R P, Bedroske, P P, Luoma, I M, Sattler, C A, Boddicker, R L, Bennani, N N, Nørgaard, P, Møller, M B, Steiniche, T, d'Amore, F & Feldman, A L 2017, ' DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma : a Danish cohort study ', Blood, vol. 130, no. 4, pp. 554-557 . https://doi.org/10.1182/blood-2016-12-755496
To the editor: Peripheral T-cell lymphomas (PTCLs) represent a group of rare hematological cancers of mature T-cell or natural killer cell origin accounting for 10% to 15% of all lymphomas.[1][1] Although many patients have poor outcomes, some achiev
Autor:
Ravikiran Vedururu, Mark A. Dawson, Ken Doig, Sarah-Jane Dawson, Stephen Q. Wong, Paul Yeh, Michael Dickinson, Sarah Ftouni, Piers Blombery, Devbarna Sinha, David Westerman, Rishu Agarwal, Tane Hunter, Chun Yew Fong
Publikováno v:
Blood. 129:1685-1690
The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on bone marrow morphology, which is associated with substantial interobserver variability. Although azacitidine is the mainstay of treatment in MDS, only half of all
Autor:
David Dingli, Angela Dispenzieri, Steven R. Zeldenrust, Morie A. Gertz, Rajshekhar Chakraborty, John A. Lust, Robert A. Kyle, Shaji Kumar, Wilson I. Gonsalves, Francis K. Buadi, Suzanne R. Hayman, Martha Q. Lacy, Ronald S. Go, S. Vincent Rajkumar, Prashant Kapoor, Nelson Leung, Eli Muchtar, Dragan Jevremovic, Yi Lin, Stephen J. Russell
Publikováno v:
Blood. 129:82-87
Multiparametric flow cytometry (MFC) in amyloid light-chain (AL) amyloidosis has not been widely adopted and, consequently, there is little information on its clinical relevance. We studied 173 patients with AL amyloidosis who underwent MFC immunophe
Autor:
Mario Cazzola, Anna Gallì, José Cervera, Torsten Haferlach, Reyes Sancho-Tello, Luca Malcovati, Ettore Rizzo, Ilaria Ambaglio, Silvia Catricalà, Ana Vicente, Chiara Elena, Manja Meggendorfer, Annette Fasan, Silvia Zibellini, Guillermo Sanz, Esther Schuler, María López-Pavía, Andrea Kuendgen, Elisabetta Molteni, Claudia Haferlach, Ulrich Germing, Esperanza Such, Erica Travaglino
Publikováno v:
BLOOD
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm with variable clinical course. To predict the clinical outcome, we previously developed a CMML-specific prognostic scoring system (CPSS) based on clinical paramet
Autor:
Ivan Spicka, Andrzej Jakubowiak, Tamas Masszi, Maria-Victoria Mateos, Jiri Minarik, Hervé Avet-Loiseau, Mihaela Obreja, Albert Oriol, William I. Bensinger, Rafael Fonseca, Georgi Mihaylov, Vesselina Goranova-Marinova, A. Keith Stewart, Vishal Kukreti, Michael Wang, Laura Rosiñol, Meletios A. Dimopoulos, Vladimir Maisnar, David A. Siegel, Ruben Niesvizky, Antonio Palumbo, Roman Hájek, Philippe Moreau, Dina Ben-Yehuda
Publikováno v:
Blood. 128:1174-1180
The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that